Clinical trial
Long Term Open Follow-up With H376/95 vs. Warfarin
NCT00206063 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00206063 |
|---|---|
| Title | Long Term Open Follow-up With H376/95 vs. Warfarin |
| Official title | Long-Term Treatment With the Oral Direct Thrombin Inhibitor Ximelagatran, Compared to Warfarin, as Stroke Prophylaxis in Patients With Atrial Fibrillation. A Long Term Follow-Up Study |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stroke Prevention in Patients With Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | EXANTA |
| Enrollment | 220 |
| Start date | Aug 1, 1999 |
| Primary completion | Jun 1, 2004 |
| Completion | Apr 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Nov 15, 2010 |
| Countries | Belgium, Czechia, Denmark, Finland, Norway, Poland, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: